CTMX
Cytomx Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$2.34Close
$398.2MMarket cap
$2.22 – $6.7552-week range
Nov 5, 2026Next report · after the close
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 5 · weaker than 95% of stocks over 12 months
- Far from its high 65% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
65%
1wk
up 0.9%
price change
1mo
down 14.0%
price change
12-month return
down 30%
market up 11% ·
its own down 39%
F-score
—
— Not assessed
Altman Z
-1.24
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
4.0×
price / book
Earnings yield
down 5.8%
EBIT / enterprise value
Cheaper than
19%
of the market · expensive
Revenue growth
down 45%
year on year
EPS growth
—
latest quarter
Sales growth
down 92%
latest quarter · -13 pts
ROE
down 18%
return on equity
Free cash margin
down 99%
-$75.8M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
6.9%
$0.16 a day · 2×ATR $2.02
RS
5 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
1.3×
vs 50-day average
Up/down volume
0.78
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 112.5% over the year, from 80m to 170m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 44.8% over the year, from $138.1M to $76.2M.
Last reported
Aug 6, 2026
Last shock
Sep 15, 2026-16% in one session2.4× volumeno filing matched-13% since
Financials
- Net -23%
- Free cash -99%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $68.4M | $37.3M | $53.2M | $101.2M | $138.1M | $76.2M |
| Operating income | -$80.5M | -$116.0M | -$101.3M | -$6.5M | $25.0M | -$22.4M |
| Net income | -$64.8M | -$115.9M | -$99.3M | -$569,000 | $31.9M | -$17.4M |
| Net margin | -95% | -311% | -187% | -1% | 23% | -23% |
| Earnings per share | -$1.40 | -$1.81 | -$1.51 | -$0.01 | $0.38 | -$0.13 |
| Free cash flow | $3.0M | -$120.6M | -$112.5M | -$56.9M | -$86.5M | -$75.8M |
| Free cash margin | 4% | -323% | -212% | -56% | -63% | -99% |
| Cash | $191.9M | $205.5M | $193.7M | $17.2M | $38.1M | $12.7M |
| Shareholders' equity | -$7.8M | -$459,000 | -$85.8M | -$47.4M | -$456,000 | $99.0M |
| Shares outstanding | 48.25m | 65.39m | 66.23m | 67.31m | 80.10m | 170.19m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 16, 2026 | Annual ↗ | Dec 31, 2025 | 75d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Mar 6, 2025 | Annual ↗ | Dec 31, 2024 | 65d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Mar 11, 2024 | Annual ↗ | Dec 31, 2023 | 71d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Results ↗ |
| Jul 27, 2026 | Director or officer change ↗ |
| Jun 22, 2026 | Director or officer change · Charter or bylaws · Shareholder vote ↗ |
| Jun 3, 2026 | Material agreement ↗ |
| May 7, 2026 | Results ↗ |
| Mar 19, 2026 | Other events ↗ |
| Mar 16, 2026 | Results ↗ |
| Nov 6, 2025 | Results ↗ |
| Aug 13, 2025 | Other events ↗ |
| Aug 7, 2025 | Results ↗ |
| Jun 13, 2025 | Director or officer change · Shareholder vote ↗ |
| May 28, 2025 | Other events ↗ |